School of Medicine

Wayne State University School of Medicine

Profile

Kaladhar B. Reddy, Ph.D.
Professor
Department of Pathology
Wayne State University School of Medicine
540 East Canfield Avenue
Detroit, MI 48201
313-577-6191
Areas
Cancer stem cells, Breast cancer, hormones, growth factor signaling, cross-talk, and drug sensitivity
Administrative Contact
Brenda Batts
Phone: (313) 577-1102
Research

The research of Dr. Reddy’s laboratory is focused on the development of novel strategies for treatment and prognosis of breast cancer by combining experimental therapeutics with cell biology. Dr. Reddy and colleagues have recently shown that PKC-d overexpression is associated with loss of endocrine sensitivity in both in vitro and in vivo. Currently, the Reddy laboratory is delineating the molecular mechanism by which alterations of PKC-a and PKC-ä leads to acquired tamoxifen resistance in breast tumors. Another focus of research in Dr. Reddy’s laboratory is on triple-negative breast cancers (TNBC). Recent data from Dr. Reddy’s laboratory suggest that combination of Cisplatin and TRAIL significantly enhances cell death in triple negative by ~60-80 % immortalized normal mammary cell line by ~15-20%. Currently, Dr. Reddy’s group is also investigating the molecular mechanisms by which cisplatin and TRAIL- induce apoptosis in Triple-Negative breast tumors.

Education

Ph.D. (1984): Osmania University, Hyderabad, AP, India

Postdoctoral Fellowship
1984-1988: University of Medicine and Dentistry of New Jersey, Newark, NJ, USA
1988-1990: The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
 

Publications

1.  Xu L, Yin S, Banerjee S, Sarkar F, and Reddy KB, 2011,  Enhanced Anticancer Effect of the Combination of Cisplatin and TRAIL in Triple-Negative Breast Tumor cells. Molecular Cancer Therapeutics 10: 550-557.

2. Yin S, Xu L, Bandyopadhyay S, Sethi S, and Reddy KB, 2011,Cisplatin and TRAIL Enhance Breast Cancer Stem Cell Death. Int. J Oncology 39: 891 898.
3. Reddy KB , 2011, Triple-Negative Breast Cancers: An updated review on treatment options. Current Oncology 18: 173-179.
4. Wong C, Wang X, Smith D, Reddy KB, Chen S: AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Breast Cancer Res. and Treat. 134: 671-81, 2012.
*5. Yin S, Xu L, Bonfil RD, Banerjee S, Sarkar F, Sethi S and Reddy KB: Tumor Initiating Cells and FZD8 play a major role in drug resistance in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics 12: 491-498, 2013 [this paper was featured as a highlight by the editors for that issue].
6. Yin S, Rishi AK and Reddy KB: Anti-estrogen resistant breast cancers cells are sensitive to cisplatin plus TRAIL treatment. Oncology Reports 33: 1475-1480, 2015.
7. Muthu M, Somagoni MS, Cheriyan VT, Munie S, Levi E, Ashour AE, Yassin AEB, Alafeefy AM, Sochacki, Polin LA, Reddy KB, Larsen SD, Singh M, and Rishi AK: Identification and testing of novel CARP-1 functional mimetic compounds as inhibitors of non-small cell lung and triple negative breast cancers. Journal of Biomedical Nanotechnology 11: 1608-1627, 2015.
8. Reddy KB: MicroRNA (miRNA) in cancer (Review). Cancer Cell International 38: 1-6, 2015.
9. Ahmad A, Ginnebaugh KR, Yin S, Bollig-Fischer A, Reddy KB and Sarkar FH: Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer (in press)